

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 AUGUST 2022

FOR

PHARMALOGIK LIMITED

PHARMALOGIK LIMITED (REGISTERED NUMBER: 08666465)

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2022**

	Page
Balance Sheet	1

BALANCE SHEET
31 AUGUST 2022

	2022		2021	
	£	£	£	£
FIXED ASSETS		1		1
CURRENT ASSETS	7,008		6,687	
CREDITORS				
Amounts falling due within one year	<u>(3,419)</u>		<u>(2,213)</u>	
NET CURRENT ASSETS		3,589		4,474
TOTAL ASSETS LESS CURRENT LIABILITIES		3,590		4,475
CREDITORS				
Amounts falling due after more than one year		<u>6,469</u>		<u>10,000</u>
NET LIABILITIES		<u>(2,879)</u>		<u>(5,525)</u>
CAPITAL AND RESERVES		<u>(2,879)</u>		<u>(5,525)</u>

NOTES TO THE FINANCIAL STATEMENTS

1. STATUTORY INFORMATION

Pharmalogik Limited is a private company, limited by shares , registered in Not specified/Other. The company's registered number and registered office address are as below:

Registered number: 08666465

Registered office: Flat 26
Mayfair Court
Observer Drive
Watford
WD18 7GA

2. AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the year was 1 (2021 - 1) .

BALANCE SHEET - continued
31 AUGUST 2022

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 August 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 August 2022 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors and authorised for issue on 15 February 2023 and were signed on its behalf by:

S P Kavlanekar - Director

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.